H.C. Wainwright reiterates buy rating on Silence Therapeutics stock

Published 13/06/2025, 12:38
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock

H.C. Wainwright maintained its buy rating and $75.00 price target on Silence Therapeutics (NASDAQ:SLN), representing significant upside potential from the current price of $5.59, following the company’s presentation of updated clinical data at the European Hematology Association Congress in Milan, Italy. InvestingPro analysis suggests the stock is slightly undervalued, with strong returns over the past three months.

On Wednesday, Silence presented new results from the Phase 1 portion of its SANRECO program evaluating divesiran, a small interfering RNA therapeutic, in patients with polycythemia vera, a chronic hematologic disorder with limited long-term treatment options.

The data showed divesiran was well tolerated across all dose levels and demonstrated sustained reductions in hematocrit and hemoglobin levels. The treatment eliminated the need for phlebotomy in well-controlled patients and confirmed target engagement through sustained hepcidin induction and iron redistribution.

H.C. Wainwright noted the results further validate divesiran’s profile as a potential first-in-class RNAi therapeutic for polycythemia vera and represent a critical de-risking milestone that supports the commercial and clinical potential of both divesiran and Silence’s broader RNAi platform.

Enrollment continues in the randomized Phase 2 portion of the SANRECO trial with full enrollment expected by year-end 2025, suggesting potential data availability in the fourth quarter of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.